| Title | Author(s) | Year | View Count |
 | Safety evaluation of telbivudine | But, DYK; Yuen, MF; Fung, J; Lai, CL | 2010 | 60 |
 | Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: A study of a large blood donor population | Yuen, MF; Lee, CK; Wong, DKH; Fung, J; Hung, I; Hsu, A; But, DYK; Cheung, TK; Chan, P; Yuen, JCH; Fung, FKC; Seto, WK; Lin, CK; Lai, CL | 2010 | 632 |
| Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B | Yuen, MF; Tanaka, Y; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; But, DYK; Chan, AOO; Wong, BCY; Mizokami, M; Lai, CL | 2009 | 439 |
| Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report | But, DYK; Lai, CL; Lim, WL; Fung, J; Wong, DKH; Yuen, MF | 2008 | 350 |
| Natural history of hepatitis-related hepatocellular carcinoma | But, DYK; Lai, CL; Yuen, MF | 2008 | 101 |
| Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels | Yuen, MF; Tanaka, Y; Shinkai, N; Poon, RT; But, DYK; Fong, DYT; Fung, J; Wong, DKH; Yuen, JCH; Mizokami, M; Lai, CL | 2008 | 426 |
|
